|
Market Closed -
London S.E.
09:05:13 23/10/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 1,894.00 GBX | -1.04% |
|
+1.69% | +3.81% |
| 23/10 | FTSE 100 slips as oil price hits five-month high | AN |
| 22/10 | UK's FTSE 100 falls as banks, miners drag; Barclays slides on job cuts | RE |
| Market Cap | 7.59TCr 10TCr 9.07TCr 8.37TCr 14TCr 9,63700Cr 14TCr 1,00800Cr 40TCr 5,04900Cr 38TCr 37TCr 15,91800Cr | P/E 2026 * |
14x | P/E 2027 * | 12.1x |
|---|---|---|---|---|---|
| Enterprise Value | 9.7TCr 13TCr 12TCr 11TCr 18TCr 12,31700Cr 18TCr 1,28800Cr 51TCr 6,45300Cr 49TCr 48TCr 20,34500Cr | EV / Sales 2026 * |
2.86x | EV / Sales 2027 * | 2.65x |
| Free-Float |
92.75% | Yield 2026 * |
3.67% | Yield 2027 * | 3.94% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
Xetra
| GS71 | Delayed | |
|
Tradegate
| GS71 | Real-time | |
|
Deutsche Boerse AG
| GS71 | Delayed | |
|
Börse Stuttgart
| GS71 | Delayed | |
|
OTC Markets
| GLAX.F | Delayed | |
|
Boerse Muenchen
| GS71 | Real-time | |
|
Mexican S.E.
| GSK1 N | End-of-day quote |
Last Transcript: GSK plc
| 1 day | -1.04% | ||
| 1 week | +1.69% | ||
| Current month | +3.38% | ||
| 1 month | +0.91% | ||
| 3 months | -1.33% | ||
| 6 months | -6.24% | ||
| Current year | +3.81% |
| 1 week | 1,851 |  | 1,917 |
| 1 month | 1,735.5 | | 2,158 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,624.5 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
James Ford
CMP | Compliance Officer | - | 01/08/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 67 | 01/09/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 22/09/26 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 18/09/26 | Buy | Director | 768 | 0.0000% | ||
| 18/09/26 | Buy | Director | 1,734 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.04% | +1.69% | +16.91% | +28.84% | 10TCr | |
| -2.54% | +1.31% | +54.27% | +114.96% | 1,13500Cr | |
| -1.42% | +3.23% | +38.56% | +74.44% | 64TCr | |
| +0.16% | +0.08% | +25.29% | +95.23% | 50TCr | |
| -0.31% | +3.09% | +44.14% | +64.80% | 38TCr | |
| -1.34% | -0.47% | +66.04% | +41.00% | 36TCr | |
| -0.68% | +2.65% | +22.98% | +50.39% | 29TCr | |
| -1.20% | +3.04% | +2.33% | +22.86% | 27TCr | |
| -1.79% | +1.57% | +50.56% | +59.08% | 24TCr | |
| -0.73% | -0.10% | +29.02% | +99.67% | 19TCr | |
| Average | -1.09% | +2.12% | +35.01% | +65.13% | 41.06TCr | |
| Weighted average by Cap. | -1.34% | +2.64% | +40.43% | +78.49% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.39TCr 4.53TCr 4.05TCr 3.74TCr 6.34TCr 4,30400Cr 6.45TCr 45TCr 18TCr 2,25500Cr 17TCr 17TCr 7,10900Cr | 3.55TCr 4.75TCr 4.24TCr 3.92TCr 6.64TCr 4,50900Cr 6.75TCr 47TCr 19TCr 2,36200Cr 18TCr 17TCr 7,44800Cr |
| Net income | 548.74Cr 734Cr 655.46Cr 605.52Cr 1.03TCr 70TCr 1.04TCr 7.29TCr 2.88TCr 37TCr 2.75TCr 2.7TCr 1,15100Cr | 622.51Cr 832.67Cr 743.58Cr 686.92Cr 1.16TCr 79TCr 1.18TCr 8.27TCr 3.27TCr 41TCr 3.12TCr 3.06TCr 1,30600Cr |
| Net Debt | 2.11TCr 2.82TCr 2.52TCr 2.33TCr 3.95TCr 2,68000Cr 4.01TCr 28TCr 11TCr 1,40400Cr 11TCr 10TCr 4,42700Cr | 1.83TCr 2.45TCr 2.19TCr 2.02TCr 3.42TCr 2,32300Cr 3.48TCr 24TCr 9.62TCr 1,21700Cr 9.18TCr 8.99TCr 3,83700Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/26/23 | GBX 1,894.00 | -1.04% | 55,16,975 |
| 22/26/22 | GBX 1,914.00 | +2.46% | 44,66,441 |
| 21/26/21 | GBX 1,868.00 | -0.03% | 1,10,52,592 |
| 20/26/20 | GBX 1,868.50 | +0.73% | 52,86,663 |
| 19/26/19 | GBX 1,855.00 | -0.40% | 49,24,879 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
